BACKGROUND Vancomycin and teicoplanin are both antibiotics that have significant antimicrobial effects on Gram-positive cocci.AIM To explore the value of teicoplanin combined with conventional(vancomycin only)anti-inf...BACKGROUND Vancomycin and teicoplanin are both antibiotics that have significant antimicrobial effects on Gram-positive cocci.AIM To explore the value of teicoplanin combined with conventional(vancomycin only)anti-infective therapy for the treatment of methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis pulmonary infections.METHODS A total of 86 patients with methicillin-resistant Staphylococcus aureus or methicillin-resistant Staphylococcus epidermidis pulmonary infections,treated in our hospital between January 2018 and February 2020,were assigned to the study and control groups using a random number table method,with 43 patients in each group.The control group received conventional treatment(vancomycin),and the study group received both teicoplanin and conventional treatment.The following indicators were assessed in both groups:the time required for symptom relief,treatment effectiveness,serum levels of inflammatory factors(procalcitonin,interleukin-1β,tumor necrosis factor-α,C-reactive protein),clinical pulmonary infection scores before and after treatment,and the incidence of adverse reactions.RESULTS Patients in the study group were observed to have faster cough and expectoration resolution,white blood cell count normalization,body temperature normalization,and rales disappearance than patients in the control group(all P<0.05);the total rate of effectiveness was 93.02%in the study group,higher than the 76.74%in the control group(P<0.05).The pre-treatment serum levels of procalcitonin,interleukin-1β,tumor necrosis factor-α,and C-reactive protein as well as the clinical pulmonary infection scores were similar among the patients in both groups.However,the post-treatment serum levels of procalcitonin,interleukin-1β,tumor necrosis factor-α,and C-reactive protein as well as the clinical pulmonary infection scores were significantly lower in the study group than in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the groups.CONCLUSION Compared with conventional(vancomycin only)therapy,teicoplanin and vancomycin combination therapy for patients with pulmonary methicillinresistant Staphylococcus aureus and methicillin-resistant Staphylococcus epidermidis infections can improve patient clinical symptoms,modulate serum inflammatory factor levels,and improve treatment efficacy,without increasing the risk of adverse reactions.展开更多
目的探讨临床分离携带psm-mec基因耐甲氧西林表皮葡萄球菌(MRSE)的SCCmec型别。方法收集临床分离并经全自动微生物鉴定系统准确鉴定的表皮葡萄球菌165株,通过PCR扩增esp和mecA基因准确鉴定MRSE,扩增psm-mec、fudoh和p221片段鉴定携带psm...目的探讨临床分离携带psm-mec基因耐甲氧西林表皮葡萄球菌(MRSE)的SCCmec型别。方法收集临床分离并经全自动微生物鉴定系统准确鉴定的表皮葡萄球菌165株,通过PCR扩增esp和mecA基因准确鉴定MRSE,扩增psm-mec、fudoh和p221片段鉴定携带psm-mec菌株。采用多重PCR对携带psm-mec基因的MRSE的mec、ccr和SCCmec进行分型。结果 138株MRSE菌株中,29株携带psm-mec基因,携带率为17.58%。多重PCR对mec和ccr分型结果显示,携带psm-mec基因MRSE均为Class A mec,但ccr型别存在明显的多样性。多重PCR对SCCmec分型结果显示,所有菌株均可扩增出Ⅱ型和/或Ⅲ型SCCmec条带,且为混合型别。结论临床分离携带psm-mec基因的MRSE的SCCmec具有同源性,以含Class A mec的携带Ⅱ型和/或Ⅲ型SCCmec为主。展开更多
基金the Beijing Tongren Hospital,Capital Medical University Institutional Review Board(Approval No.TRECKY2020-100).
文摘BACKGROUND Vancomycin and teicoplanin are both antibiotics that have significant antimicrobial effects on Gram-positive cocci.AIM To explore the value of teicoplanin combined with conventional(vancomycin only)anti-infective therapy for the treatment of methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis pulmonary infections.METHODS A total of 86 patients with methicillin-resistant Staphylococcus aureus or methicillin-resistant Staphylococcus epidermidis pulmonary infections,treated in our hospital between January 2018 and February 2020,were assigned to the study and control groups using a random number table method,with 43 patients in each group.The control group received conventional treatment(vancomycin),and the study group received both teicoplanin and conventional treatment.The following indicators were assessed in both groups:the time required for symptom relief,treatment effectiveness,serum levels of inflammatory factors(procalcitonin,interleukin-1β,tumor necrosis factor-α,C-reactive protein),clinical pulmonary infection scores before and after treatment,and the incidence of adverse reactions.RESULTS Patients in the study group were observed to have faster cough and expectoration resolution,white blood cell count normalization,body temperature normalization,and rales disappearance than patients in the control group(all P<0.05);the total rate of effectiveness was 93.02%in the study group,higher than the 76.74%in the control group(P<0.05).The pre-treatment serum levels of procalcitonin,interleukin-1β,tumor necrosis factor-α,and C-reactive protein as well as the clinical pulmonary infection scores were similar among the patients in both groups.However,the post-treatment serum levels of procalcitonin,interleukin-1β,tumor necrosis factor-α,and C-reactive protein as well as the clinical pulmonary infection scores were significantly lower in the study group than in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the groups.CONCLUSION Compared with conventional(vancomycin only)therapy,teicoplanin and vancomycin combination therapy for patients with pulmonary methicillinresistant Staphylococcus aureus and methicillin-resistant Staphylococcus epidermidis infections can improve patient clinical symptoms,modulate serum inflammatory factor levels,and improve treatment efficacy,without increasing the risk of adverse reactions.
文摘目的探讨临床分离携带psm-mec基因耐甲氧西林表皮葡萄球菌(MRSE)的SCCmec型别。方法收集临床分离并经全自动微生物鉴定系统准确鉴定的表皮葡萄球菌165株,通过PCR扩增esp和mecA基因准确鉴定MRSE,扩增psm-mec、fudoh和p221片段鉴定携带psm-mec菌株。采用多重PCR对携带psm-mec基因的MRSE的mec、ccr和SCCmec进行分型。结果 138株MRSE菌株中,29株携带psm-mec基因,携带率为17.58%。多重PCR对mec和ccr分型结果显示,携带psm-mec基因MRSE均为Class A mec,但ccr型别存在明显的多样性。多重PCR对SCCmec分型结果显示,所有菌株均可扩增出Ⅱ型和/或Ⅲ型SCCmec条带,且为混合型别。结论临床分离携带psm-mec基因的MRSE的SCCmec具有同源性,以含Class A mec的携带Ⅱ型和/或Ⅲ型SCCmec为主。
